Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity.

Oncolytic viruses are genetically altered replication-competent viruses that infect, and reproduce in, cancer cells but do not harm normal cells. On lysis of the infected cells, the newly formed viruses burst out and infect other tumor cells. Experiments with injecting mutant herpes simplex virus 1 (hrR3) into glioma implanted in brains of rats show lack of efficacy in eradicating the cancer. This failure is attributed to interference by the immune system. Initial pretreatment with immunosuppressive agent cyclophosphamide reduces the percentage of immune cells. We introduce a mathematical model and use it to determine how different protocols of cyclophosphamide treatment and how increased burst size of the mutated virus will affect the growth of the cancer. One of our conclusions is that the diameter of the cancer will decrease from 4 mm to eventually 1 mm if the burst size of the virus is triple that which is currently available. The effect of repeated cyclophosphamide treatment is to maintain a low density of uninfected cells in the tumor, thus reducing the probability of migration of tumor cells to other locations in the brain.

[1]  B. Bodey,et al.  MTH-68/H Oncolytic Viral Treatment in Human High-Grade Gliomas , 2004, Journal of Neuro-Oncology.

[2]  H. Sjöström,et al.  A mouse aminopeptidase N is a marker for antigen‐presenting cells and appears to be co‐expressed with major histocompatibility complex class II molecules , 1993, European journal of immunology.

[3]  A. Friedman,et al.  Analysis of a model of a virus that replicates selectively in tumor cells , 2003, Journal of mathematical biology.

[4]  J. Marshall,et al.  Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Martuza,et al.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial , 2000, Gene Therapy.

[6]  S. Hotte,et al.  Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. , 2003, Current opinion in molecular therapeutics.

[7]  R. Martuza,et al.  Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas , 1995, Nature Medicine.

[8]  G. Batchelor,et al.  An Introduction to Fluid Dynamics , 1968 .

[9]  M. Gulley,et al.  A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  J. Simons,et al.  Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. , 1997, Cancer research.

[11]  J. Olson,et al.  A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  V. P. Zhivoglyadov,et al.  Kinetic approach and estimation of the parameters of cellular interaction between the immunity system and a tumor. , 1993, Archivum immunologiae et therapiae experimentalis.

[13]  J F Fowler,et al.  Rapid repopulation in radiotherapy: a debate on mechanism. The phantom of tumor treatment--continually rapid proliferation unmasked. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  M. Coffey,et al.  Reovirus therapy of tumors with activated Ras pathway. , 1998, Science.

[15]  J. Nemunaitis,et al.  Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity , 2001, Gene Therapy.

[16]  M. Chaplain,et al.  Spatio-temporal dynamics of the immune system response to cancer , 1997 .

[17]  F. Shanahan,et al.  The Fas counterattack: cancer as a site of immune privilege. , 1999, Immunology today.

[18]  F. Khuri,et al.  Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. , 2000, Cancer research.

[19]  A. Denman.  Cellular and Molecular Immunology , 1992 .

[20]  T. Wheldon,et al.  Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  H. Wakimoto,et al.  Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells , 2003, Gene Therapy.

[22]  A. Maclean,et al.  Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma , 2000, Gene Therapy.

[23]  R. Petty,et al.  The potential for efficacy of the modified (ICP 34.5−) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study , 2002, Gene Therapy.

[24]  L. Wein,et al.  Modeling and analysis of a virus that replicates selectively in tumor cells , 2001, Bulletin of mathematical biology.

[25]  L. Wein,et al.  Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response , 2004, Bulletin of mathematical biology.

[26]  E. Chiocca.  Oncolytic viruses , 2002, Nature Reviews Cancer.

[27]  H. Wakimoto,et al.  Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis , 2004, Gene Therapy.

[28]  Gieri Simonett,et al.  Mathematical models in medical and health science , 1998 .

[29]  A. I. Yudin,et al.  Diffusion of macromolecules and virus-like particles in human cervical mucus. , 2001, Biophysical journal.

[30]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.